Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Stupp Regimen for Newly Diagnosed Glioblastoma
NCT04959500Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of anlotinib in glioblastoma (GBM) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 24 months. Started Jul 2021; status: active, not recruiting.
02
Drugs
anlotinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04959500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04959500.